Baidu
map

J Hepatol:丙酮酸脱氢酶复合物和乳酸脱氢酶是治疗急性肝衰竭的靶点

2018-03-31 MedSci MedSci原创

PDHC和LDH转移到细胞核,是治疗急性肝衰竭的靶点。

研究背景:急性肝衰竭是肝功能迅速恶化,导致高死亡率和高发病率。代谢酶可以在细胞核中转移,以调节组蛋白乙酰化和基因表达。

研究方法:在暴露于各种肝脏毒物(CD95-Ab、α-毒蕈环肽、对乙酰氨基酚)的小鼠肝组织的细胞核中评价丙酮酸脱氢酶复合物(PDHC)和乳酸脱氢酶(LDH)的水平和活性。采用RNA-seq对急性肝功能衰竭小鼠的全基因组基因表达谱进行检测,并进行基因本体富集分析。在暴露于各种肝脏毒物的小鼠中,评价组蛋白乙酰转移酶抑制剂-garcinol和LDH抑制剂-galloflavin在减轻肝损伤上面的疗效。

研究结果:在急性肝功能衰竭的小鼠的肝细胞浆体和细胞核中,PDHC和LDH的水平和活动均增加。细胞核PDHC和LDH的增加与细胞核中乙酰辅酶A和乳酸的浓度增加和组蛋白H3超乙酰化有关。急性肝功能衰竭小鼠肝脏的基因表达提示,组蛋白H3乙酰化的增加诱导了对损伤的反应的基因的表达。组蛋白乙酰转移酶抑制剂-garcinol降低组蛋白乙酰化,降低肝损伤,改善急性肝衰竭小鼠的生存。暴露于促凋亡刺激的细胞中,PDHC或LDH的敲除,提高了细胞生存能力。在急性肝功能衰竭的小鼠中,LDH抑制剂-galloflavin被发现抑制了PDHC的活性、减轻了肝坏死、凋亡和促炎细胞因子表达。

研究结论:PDHC和LDH转移到细胞核,是治疗急性肝衰竭的靶点。

原始出处

Ferriero R, Nusco E, De Cegli R, et al. Pyruvate dehydrogenase complex and lactate dehydrogenase as targets for therapy of acute liver failure. J Hepatol, 2018 Mar 23. doi: 10.1016/j.jhep.2018.03.016.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1635799, encodeId=e2951635e9906, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Thu Oct 25 08:36:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910613, encodeId=ca6219106135a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Dec 29 07:36:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290476, encodeId=06ca12904e632, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427066, encodeId=0d88142e066f4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301713, encodeId=5c56301e13fa, content=学习了.有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Apr 01 09:47:34 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301601, encodeId=430a301601f4, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 01 00:32:28 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1635799, encodeId=e2951635e9906, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Thu Oct 25 08:36:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910613, encodeId=ca6219106135a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Dec 29 07:36:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290476, encodeId=06ca12904e632, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427066, encodeId=0d88142e066f4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301713, encodeId=5c56301e13fa, content=学习了.有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Apr 01 09:47:34 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301601, encodeId=430a301601f4, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 01 00:32:28 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1635799, encodeId=e2951635e9906, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Thu Oct 25 08:36:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910613, encodeId=ca6219106135a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Dec 29 07:36:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290476, encodeId=06ca12904e632, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427066, encodeId=0d88142e066f4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301713, encodeId=5c56301e13fa, content=学习了.有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Apr 01 09:47:34 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301601, encodeId=430a301601f4, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 01 00:32:28 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1635799, encodeId=e2951635e9906, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Thu Oct 25 08:36:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910613, encodeId=ca6219106135a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Dec 29 07:36:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290476, encodeId=06ca12904e632, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427066, encodeId=0d88142e066f4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301713, encodeId=5c56301e13fa, content=学习了.有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Apr 01 09:47:34 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301601, encodeId=430a301601f4, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 01 00:32:28 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2018-04-02 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1635799, encodeId=e2951635e9906, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Thu Oct 25 08:36:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910613, encodeId=ca6219106135a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Dec 29 07:36:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290476, encodeId=06ca12904e632, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427066, encodeId=0d88142e066f4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301713, encodeId=5c56301e13fa, content=学习了.有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Apr 01 09:47:34 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301601, encodeId=430a301601f4, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 01 00:32:28 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2018-04-01 明崖

    学习了.有用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1635799, encodeId=e2951635e9906, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Thu Oct 25 08:36:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910613, encodeId=ca6219106135a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Dec 29 07:36:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290476, encodeId=06ca12904e632, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427066, encodeId=0d88142e066f4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 02 11:36:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301713, encodeId=5c56301e13fa, content=学习了.有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Apr 01 09:47:34 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301601, encodeId=430a301601f4, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 01 00:32:28 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2018-04-01 飛歌

    厉害了我的哥

    0

相关资讯

GUT:MerTK表达肝巨噬细胞促进急性肝衰竭中炎症的消除

急性肝衰竭(ALF)的特征在于大量的肝细胞死亡以及坏死区域大量浸润的骨髓细胞导致的肝脏炎症。治疗急性肝炎的相关机制在很大程度上仍然是未知的。近期,一项发表在杂志GUT上的研究旨在评估在ALF期间Mer酪氨酸激酶(MerTK)的影响,并且研究了微环境介体、分泌白细胞蛋白酶抑制剂(SLPI)是如何控制这种反应的。此项研究采用流式细胞术、免疫组织化学、共聚焦显像和基因表达分析确定了ALF、健康和疾病对照

GUT:乙型肝炎病毒相关急性肝衰竭的新诊断标准和预后评分!

目前,不考虑病因,而是基于肝硬化的急性肝衰竭(ACLF)的定义仍然存在争议。基于此,近期,一项发表在杂志GUT上的前瞻性研究旨在评估乙型肝炎病毒相关ACLF(HBV-ACLF)患者的临床病理特征,并为这些患者制定了新的诊断标准和预后评分。此项研究在中国13个肝脏中心中选取了1322例慢性乙型肝炎(CHB)肝硬化或严重肝损伤急性失代偿性的住院患者的临床资料,用于制定新的诊断和预后标准。此项研究结果显

病例分享:罕见病因导致急性肝衰竭一例

急性肝衰竭(ALF)可因病毒感染、药物、中毒、自身免疫反应等所致,但还有相当一部分患者诱因不明。葡萄牙学者近日报告了一个罕见的由于乳腺癌弥漫性肝转移而诱发的急性肝衰竭病例。

Hepatology:急性肝损伤/肝衰竭患者降氨新研究!

目前,脑水肿仍然是急性肝功能衰竭(ALF)患者发病和死亡的重要原因,并且其与血氨水平的升高有关。L-鸟氨酸苯乙酸(OPA)可以通过促进苯乙酰谷氨酰胺(PAGN)的肾脏排泄而降低氨水平,从而降低脑水肿的风险。近期,一项发表在杂志Hepatology上的研究评估了OPA在ALF和急性肝损伤(ALI)患者(包括肾衰竭患者)中的安全性、耐受性和药代动力学。此项研究共招募了47例ALI/ALF和氨≥60μM

Hepatology:哪种肾脏替代方式与急性肝衰竭的血氨水平和死亡率降低有关?

高血氨症与急性肝衰竭(ALF)患者的颅内高血压和死亡率有关。近期,一项发表在杂志Hepatology上的研究评估了肾脏替代疗法(RRT)对ALF患者血清氨的水平和结局的影响。此项研究为来自美国 1998/01-2016/12的ALF研究组注册表的连续ALF患者的多中心队列研究。首先,研究者们评估了血氨与肝性脑病(HE)和21天无移植生存(TFS)(n = 1186)之间的关系。其次,研究了RRT对

慢加急性肝衰竭诊断有中国标准

浙江大学医学院附属第一医院李兰娟院士团队的李君教授课题组联合上海交通大学医学院附属瑞金医院、北京佑安医院等12家国内著名医院的肝病中心,历经5年的前瞻性大样本研究,建立了慢加急性肝衰竭(ACLF)诊断与预后评估的中国标准(COSSH-ACLF),该研究结果于9月19日在线发表于《胃肠病》杂志上。

Baidu
map
Baidu
map
Baidu
map